Literature DB >> 12477841

The dimer interfaces of protease and extra-protease domains influence the activation of protease and the specificity of GagPol cleavage.

Steven C Pettit1, Sergei Gulnik, Lori Everitt, Andrew H Kaplan.   

Abstract

Activation of the human immunodeficiency virus type 1 (HIV-1) protease is an essential step in viral replication. As is the case for all retroviral proteases, enzyme activation requires the formation of protease homodimers. However, little is known about the mechanisms by which retroviral proteases become active within their precursors. Using an in vitro expression system, we have examined the determinants of activation efficiency and the order of cleavage site processing for the protease of HIV-1 within the full-length GagPol precursor. Following activation, initial cleavage occurs between the viral p2 and nucleocapsid proteins. This is followed by cleavage of a novel site located in the transframe domain. Mutational analysis of the dimer interface of the protease produced differential effects on activation and specificity. A subset of mutations produced enhanced cleavage at the amino terminus of the protease, suggesting that, in the wild-type precursor, cleavages that liberate the protease are a relatively late event. Replacement of the proline residue at position 1 of the protease dimer interface resulted in altered cleavage of distal sites and suggests that this residue functions as a cis-directed specificity determinant. In summary, our studies indicate that interactions within the protease dimer interface help determine the order of precursor cleavage and contribute to the formation of extended-protease intermediates. Assembly domains within GagPol outside the protease domain also influence enzyme activation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12477841      PMCID: PMC140564          DOI: 10.1128/jvi.77.1.366-374.2003

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  54 in total

1.  The use of native T7 DNA polymerase for site-directed mutagenesis.

Authors:  K Bebenek; T A Kunkel
Journal:  Nucleic Acids Res       Date:  1989-07-11       Impact factor: 16.971

2.  Complete mutagenesis of the HIV-1 protease.

Authors:  D D Loeb; R Swanstrom; L Everitt; M Manchester; S E Stamper; C A Hutchison
Journal:  Nature       Date:  1989-08-03       Impact factor: 49.962

3.  Kinetic and modeling studies of S3-S3' subsites of HIV proteinases.

Authors:  J Tözsér; I T Weber; A Gustchina; I Bláha; T D Copeland; J M Louis; S Oroszlan
Journal:  Biochemistry       Date:  1992-05-26       Impact factor: 3.162

4.  Analysis of retroviral protease cleavage sites reveals two types of cleavage sites and the structural requirements of the P1 amino acid.

Authors:  S C Pettit; J Simsic; D D Loeb; L Everitt; C A Hutchison; R Swanstrom
Journal:  J Biol Chem       Date:  1991-08-05       Impact factor: 5.157

5.  Specific inhibitor of human immunodeficiency virus proteinase prevents the cytotoxic effects of a single-chain proteinase dimer and restores particle formation.

Authors:  H G Kräusslich
Journal:  J Virol       Date:  1992-01       Impact factor: 5.103

6.  Conserved folding in retroviral proteases: crystal structure of a synthetic HIV-1 protease.

Authors:  A Wlodawer; M Miller; M Jaskólski; B K Sathyanarayana; E Baldwin; I T Weber; L M Selk; L Clawson; J Schneider; S B Kent
Journal:  Science       Date:  1989-08-11       Impact factor: 47.728

7.  Identification of a region in the Pr55gag-polyprotein essential for HIV-1 particle formation.

Authors:  A von Poblotzki; R Wagner; M Niedrig; G Wanner; H Wolf; S Modrow
Journal:  Virology       Date:  1993-04       Impact factor: 3.616

8.  Partial inhibition of the human immunodeficiency virus type 1 protease results in aberrant virus assembly and the formation of noninfectious particles.

Authors:  A H Kaplan; J A Zack; M Knigge; D A Paul; D J Kempf; D W Norbeck; R Swanstrom
Journal:  J Virol       Date:  1993-07       Impact factor: 5.103

9.  A heptanucleotide sequence mediates ribosomal frameshifting in mammalian cells.

Authors:  H Reil; H Kollmus; U H Weidle; H Hauser
Journal:  J Virol       Date:  1993-09       Impact factor: 5.103

10.  Functional chimeras of the Rous sarcoma virus and human immunodeficiency virus gag proteins.

Authors:  R P Bennett; T D Nelle; J W Wills
Journal:  J Virol       Date:  1993-11       Impact factor: 5.103

View more
  40 in total

1.  Computational analysis of HIV-1 protease protein binding pockets.

Authors:  Gene M Ko; A Srinivas Reddy; Sunil Kumar; Barbara A Bailey; Rajni Garg
Journal:  J Chem Inf Model       Date:  2010-10-25       Impact factor: 4.956

2.  The nature of the N-terminal amino acid residue of HIV-1 RNase H is critical for the stability of reverse transcriptase in viral particles.

Authors:  Guney Boso; Claes Örvell; Nikunj V Somia
Journal:  J Virol       Date:  2014-11-12       Impact factor: 5.103

3.  Equilibrium unfolding of kinetically stable serine protease milin: the presence of various active and inactive dimeric intermediates.

Authors:  Subhash Chandra Yadav; Medicherla V Jagannadham; Suman Kundu
Journal:  Eur Biophys J       Date:  2010-03-24       Impact factor: 1.733

4.  HIV-1 protease dimer interface mutations that compensate for viral reverse transcriptase instability in infectious virions.

Authors:  Isabel Olivares; Alok Mulky; Peter I Boross; József Tözsér; John C Kappes; Cecilio López-Galíndez; Luis Menéndez-Arias
Journal:  J Mol Biol       Date:  2007-07-03       Impact factor: 5.469

5.  Uncoupling human immunodeficiency virus type 1 Gag and Pol reading frames: role of the transframe protein p6* in viral replication.

Authors:  Andreas Leiherer; Christine Ludwig; Ralf Wagner
Journal:  J Virol       Date:  2009-04-29       Impact factor: 5.103

6.  F99 is critical for dimerization and activation of South African HIV-1 subtype C protease.

Authors:  Previn Naicker; Palesa Seele; Heini W Dirr; Yasien Sayed
Journal:  Protein J       Date:  2013-10       Impact factor: 2.371

7.  C-Terminal HIV-1 Transframe p6* Tetrapeptide Blocks Enhanced Gag Cleavage Incurred by Leucine Zipper Replacement of a Deleted p6* Domain.

Authors:  Fu-Hsien Yu; Kuo-Jung Huang; Chin-Tien Wang
Journal:  J Virol       Date:  2017-04-28       Impact factor: 5.103

Review 8.  The choreography of HIV-1 proteolytic processing and virion assembly.

Authors:  Sook-Kyung Lee; Marc Potempa; Ronald Swanstrom
Journal:  J Biol Chem       Date:  2012-10-05       Impact factor: 5.157

9.  Variability at human immunodeficiency virus type 1 subtype C protease cleavage sites: an indication of viral fitness?

Authors:  Tulio de Oliveira; Susan Engelbrecht; Estrelita Janse van Rensburg; Michelle Gordon; Karen Bishop; Jan zur Megede; Susan W Barnett; Sharon Cassol
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

10.  Human immunodeficiency virus (HIV) type 1 transframe protein can restore activity to a dimerization-deficient HIV protease variant.

Authors:  Nathalie Dautin; Gouzel Karimova; Daniel Ladant
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.